1999
Selective Speech Perception Alterations in Schizophrenic Patients Reporting Hallucinated Voices
Hoffman RE, Rapaport J, Mazure CM, Quinlan DM. Selective Speech Perception Alterations in Schizophrenic Patients Reporting Hallucinated Voices. American Journal Of Psychiatry 1999, 156: 393-399. PMID: 10080554, DOI: 10.1176/ajp.156.3.393.Peer-Reviewed Original ResearchConceptsSpeech perceptionSchizophrenia spectrum disordersMasked speechSpectrum disorderAuditory continuous performance taskNeural network computer simulationSentence repetition performanceContinuous performance taskSentence repetition taskNonhallucinating patientsRepetition taskAttentional deficitsAttention impairmentRepetition performancePerformance taskPerception alterationHallucinated voicesMemory systemTaskPerceptionSpeechSchizophrenic patientsNonlanguageDisordersMemory
1995
DSM-III-R Axis IV: Clinician Reliability and Comparability to Patients’ Reports of Stressor Severity
Mazure CM, Kincare P, Schaffer CE. DSM-III-R Axis IV: Clinician Reliability and Comparability to Patients’ Reports of Stressor Severity. Psychiatry 1995, 58: 56-64. PMID: 7792323, DOI: 10.1080/00332747.1995.11024711.Peer-Reviewed Original ResearchMeSH KeywordsAdaptation, PsychologicalAdultAgedBipolar DisorderDementiaDepressive DisorderFemaleHumansMaleMiddle AgedPatient AdmissionPersonality AssessmentPsychiatric Status Rating ScalesPsychometricsPsychotic DisordersReproducibility of ResultsRisk FactorsSchizophreniaSchizophrenic PsychologySomatoform DisordersStress, PsychologicalConceptsPsychosocial stressorsAxis IVClinical setting todayMultiaxial diagnostic systemImportant precipitantsExacerbation of psychopathologyPatient reportsPatients' appraisalPsychiatric disordersClinical ratingsClinician reliabilityObjective ratingsSeverityExacerbationStressor severityNosological systemsReportStressorsSubjective appraisalClinicians
1992
Lithium in combination with perphenazine: effect on plasma monoamine metabolites
Bowers M, Mazure C, Nelson J, Jatlow P. Lithium in combination with perphenazine: effect on plasma monoamine metabolites. Biological Psychiatry 1992, 32: 1102-1107. PMID: 1477190, DOI: 10.1016/0006-3223(92)90190-b.Peer-Reviewed Original ResearchDrug-responsive symptoms during early neuroleptic treatment
Mazure C, Nelson J, Jatlow P, Bowers M. Drug-responsive symptoms during early neuroleptic treatment. Psychiatry Research 1992, 41: 147-154. PMID: 1574541, DOI: 10.1016/0165-1781(92)90106-d.Peer-Reviewed Original ResearchConceptsDrug responseEarly drug responseDays of treatmentIdentification of symptomsNeuroleptic treatmentSerum concentrationsNeuroleptic drugsNeurochemical mechanismsPositive symptomsSymptomsProgressive phaseDrug actionConceptual disorganizationMultiple regression analysisRegression analysisTreatmentPsychosisSeverityHallucinationsResponse
1991
Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis
Mazure C, Nelson J, Jatlow P, Bowers M. Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis. Biological Psychiatry 1991, 30: 475-482. PMID: 1932395, DOI: 10.1016/0006-3223(91)90309-a.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdolescentAdultBipolar DisorderChromatography, High Pressure LiquidDepressive DisorderDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHomovanillic AcidHumansMaleMethoxyhydroxyphenylglycolMiddle AgedPerphenazinePrognosisProspective StudiesPsychiatric Status Rating ScalesPsychotic DisordersSchizophreniaSchizophrenic PsychologyConceptsPlasma homovanillic acidHomovanillic acidFree homovanillic acidClinical responseEarly clinical responsePlasma-free homovanillic acidUseful clinical predictorClinical predictorsNeuroleptic treatmentAcute psychosisDopamine metabolismNoradrenergic functioningMethoxyhydroxyphenylglycolFavorable responsePsychotic inpatientsGood responseSignificant decline
1990
The relationship between blood perphenazine levels, early resolution of psychotic symptoms, and side effects.
Mazure CM, Nelson JC, Jatlow PI, Kincare P, Bowers MB. The relationship between blood perphenazine levels, early resolution of psychotic symptoms, and side effects. The Journal Of Clinical Psychiatry 1990, 51: 330-4. PMID: 2199431.Peer-Reviewed Original ResearchMeSH KeywordsAdultAkathisia, Drug-InducedBasal Ganglia DiseasesBenztropineClinical Trials as TopicDose-Response Relationship, DrugDrug Administration ScheduleFemaleHospitalizationHumansMaleParkinson Disease, SecondaryPerphenazinePsychiatric Status Rating ScalesPsychotic DisordersSchizophreniaSchizophrenic PsychologyConceptsExtrapyramidal side effectsSide effectsBrief Psychiatric Rating Scale (BPRS) totalSerious extrapyramidal side effectsIndividual BPRS itemsResolution of psychosisEarly resolutionBlood level monitoringBlood levelsIndividual symptomsTherapeutic thresholdPsychotic symptomsPsychotic inpatientsScale totalDrug efficacyBPRS itemsPerphenazine concentrationSymptomsPsychosisPerphenazineLevel monitoringPsychotogenic Drug Use and Neuroleptic Response
Bowers MB, Mazure CM, Nelson JC, Jatlow PI. Psychotogenic Drug Use and Neuroleptic Response. Schizophrenia Bulletin 1990, 16: 81-85. PMID: 1970670, DOI: 10.1093/schbul/16.1.81.Peer-Reviewed Original ResearchConceptsDrug useNeuroleptic responseDual diagnosis patientsDoses of haloperidolPsychotic malesDevelopment of psychosisPsychotogenic drugsDiagnosis patientsDopaminergic mechanismsPrior historyPsychotic disordersMeans of effectsRefractorinessSeparate studiesMalesEarly stagesHaloperidolPatientsIllnessPsychosisDoses